Lyra Therapeutics (NASDAQ:LYRA) Shares Down 5% – What’s Next?

Shares of Lyra Therapeutics, Inc. (NASDAQ:LYRA) fell 5% during trading on Wednesday . The company traded as low as $0.4750 and last traded at $0.4750. Approximately 204 shares changed hands during trading, a decline of 100% from the average daily volume of 53,314 shares. The stock had previously closed at $0.50.

Lyra Therapeutics Stock Down 5.0%

The stock has a market cap of $843,125.00, a PE ratio of -0.02 and a beta of 0.68. The firm has a fifty day moving average of $0.62 and a 200 day moving average of $0.96.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Sabby Management LLC lifted its stake in Lyra Therapeutics by 37.2% during the fourth quarter. Sabby Management LLC now owns 175,158 shares of the company’s stock worth $539,000 after purchasing an additional 47,534 shares during the last quarter. Artia Global Partners LP acquired a new position in Lyra Therapeutics in the fourth quarter valued at approximately $27,000. Citadel Advisors LLC purchased a new position in Lyra Therapeutics in the third quarter valued at approximately $128,000. Bank of America Corp DE increased its stake in Lyra Therapeutics by 33.7% in the second quarter. Bank of America Corp DE now owns 28,542 shares of the company’s stock valued at $256,000 after purchasing an additional 7,190 shares during the last quarter. Finally, DRW Securities LLC acquired a new stake in Lyra Therapeutics during the fourth quarter worth approximately $52,000. Hedge funds and other institutional investors own 95.62% of the company’s stock.

About Lyra Therapeutics

Lyra Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted drug delivery therapies for diseases of the ear, nose and throat (ENT). Leveraging its proprietary Therapeutic Drug Delivery (TDD) platform, the company designs bioresorbable, steroid-eluting implants that provide sustained, localized release of medication directly to affected tissue. This approach aims to improve patient outcomes by reducing the need for repeated administration and minimizing systemic side effects.

The company’s lead product candidate, LYR-210, is an implantable matrix that delivers the corticosteroid mometasone furoate over several months to treat chronic rhinosinusitis (CRS).